BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30

• 

  Layoffs

  Guessing Game: Former HHS Workers’ Next Stops Unclear

  Where thousands of former Health and Human Services employees will work next is unknown, but biopharma companies likely aren’t the main destination. Two biopharma executives discuss potential landing spots.

  April 24, 2025

   · 

  5 min read

   · 

  Angela Gabriel
• 

  IN PARTNERSHIP WITH DIA

  Economic Challenges, Strategic Investments: Reshaping the Women’s Health Landscape

  In this episode presented by DIA, BioSpace’s head of insights Lori Ellis discusses how collaboration and investment shape the the future of women’s health with Martin Hodosi, partner at Kearney and Melissa Laitner, director of strategic initiatives at the National Academy of Medicine.

  April 24, 2025

   · 

  1 min read

   · 

  Lori Ellis
• 

  Job Trends

  Massive Investment in US Manufacturing Triggers Wave of Career Opportunities

  Companies are announcing significant investments in U.S. manufacturing in response to looming tariffs. An AstraZeneca executive and Eli Lilly and Novo Nordisk spokespeople discuss potential job and skill-building opportunities and where manufacturing might head in the future.

  April 24, 2025

   · 

  6 min read

   · 

  Angela Gabriel
• 

  Regulatory

  Vanda Escalates Vendetta Against FDA, Blasts ‘Bureaucrats’ for Delaying Stomach Drug

  The tradipitant saga stretches back to September 2024, when the FDA declined to approve Vanda’s drug in gastroparesis, a stomach condition characterized by delayed gastric emptying.

  April 24, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Startups

  Novartis-, Sanofi-Backed Granite Brings $100M to Compete in Crowded I&I Space

  Granite will focus on two antibody therapies, both targeting crucial players in the inflammatory cascade to address autoimmune diseases.

  April 24, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Sponsored

  Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage

  Founded in 2007, Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients with rare neurodegenerative diseases

  April 24, 2025

   · 

  6 min read
• 

  Vaccines

  Sales of Merck’s 4-Way Measles Vaccine Take Hit as US Dips Into Stockpile

  Proquad is rarely a newsmaker from Merck’s earnings, but this time around, the U.S. has had a series of measles outbreaks. Sales of the vaccine were $539 million for the quarter, a 5% decline from the same period in 2024.

  April 24, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Startups

  Etiome Steps Out of Stealth With $50M to Address Disease At The ‘Silent Stage’

  With a new raise provided by Flagship Pioneering, the new company is aiming to find “the silent window” before disease symptoms set in.

  April 24, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  Earnings

  Tariff Uncertainty Reigns Over Q1 Earnings, With Merck Taking $200M Blow So Far

  Merck, Bristol Myers Squibb, Sanofi and Roche had little clarity on the potential impact of President Donald Trump’s pharmaceutical tariffs but many companies are already preparing for what’s to come.

  April 24, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Tariffs

  Roche in ‘Very, Very Good Position’ To Weather Trump Tariffs but M&A May Suffer

  Roche’s exposure to the tariffs is mostly limited to four medicines, three of which it already produces in the U.S., according to CEO Thomas Schinecker, who declined to reveal what these assets are.

  April 24, 2025

   · 

  2 min read

   · 

  Tristan Manalac